Human PD-L1 (CD274) activation kit by CRISPRa

CAT#: GA109256

CD274 CRISPRa kit - CRISPR gene activation of human CD274 molecule

Product Images

Specifications

Product Data

• Format: 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug)
• Symbol: CD274
• Locus ID: 29126
• Kit Components:

  GA109256G1, PD-L1 gRNA vector 1 in pCas-Guide-GFP-CRISPRa

  GA109256G2, PD-L1 gRNA vector 2 in pCas-Guide-GFP-CRISPRa

  GA109256G3, PD-L1 gRNA vector 3 in pCas-Guide-GFP-CRISPRa

  1 CRISPRa-Enhancer vector, SKU GE100056

  1 CRISPRa scramble vector, SKU GE100077

• Disclaimer: These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPRa SAM technology. The efficiency of the activation can be affected by many factors, including nucleosome occupancy status, chromatin structure and the gene expression level of the target, etc.

Reference Data

• RefSeq: NM_001267706, NM_001314029, NM_014143, NR_052005
• UniProt ID: Q9NZQ7
• Synonyms: B7-H; B7H1; PD-L1; PDCD1L1; PDCD1LG1; PDL1
• Summary: This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015]